74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Sartorius AG
Closed
SectorHealthcare
200 -7.02
Overview
Share price change
24h
Min
199.3
Max
216
Income | 16M 30M |
|---|---|
Sales | 113M 907M |
P/E Sector Avg | 175.082 63.778 |
EPS | 1.04 |
Dividend yield | 0.33 |
Profit margin | 3.308 |
Employees | 12,826 |
EBITDA | -33M 149M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +23.09% upside |
Dividend yield Sector Avg | 0.33% 2.39% |
|---|
Market Cap | 3.5B 13B |
|---|---|
Previous open | 207.02 |
Previous close | 200 |
News Sentiment
By Acuity
21%
79%
47 / 386 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Sartorius AG Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Sartorius AG Forecast
Price Target
By TipRanks
23.09% upside
12 Months Forecast
Average 265.5 EUR 23.09%
High 340 EUR
Low 185 EUR
Based on 13 Wall Street analysts offering 12 month price targets forSartorius AG - Dist in the last 3 months.
Sentiment
By Acuity
47 / 386 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Sartorius AG
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers. It also provides live-cell analysis systems, reagents and consumables, support and services, and live-cell imaging and analysis software; contract manufacturing and integration, membranes and devices, weigh cells, and data analytics, as well as connectivity, and pipetting and dispensing modules; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and biolayer interferometry products. In addition, the company offers water purification systems; surface plasmon resonance; lab balances, pipette calibration, mass comparators and metrology, moisture analyzers, equipment manufacturer cells, weights and weight sets, paint mixing solutions, and weighing accessories; and process filtration. Further, the company provides bioprocess consulting and engineering, biologics testing, media and process, instrument, octet service and support, and validation services. It serves the life science research, biopharmaceutical manufacturing, pharmaceutical quality control, cell and gene therapy, and applied industries. Sartorius Aktiengesellschaft was founded in 1870 and is headquartered in Göttingen, Germany.
